A retrospective, multicenter, observational study of Secukinumab in patients with axial spondyloarthritis
Latest Information Update: 21 Jun 2021
At a glance
- Drugs Secukinumab (Primary) ; Tumour necrosis factor inhibitors
- Indications Ankylosing spondylitis; Axial spondyloarthritis
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.